TriNetra™ uses a proprietary technology developed by the Company to detect breast cancer-specific circulating tumor cells (CTCs). Studies have shown that TriNetra™ It can detect even stage 0 (DCIS) and stage 1 cancers with high precision. The test requires only 5 ml of blood and is indicated for asymptomatic women over 40 with a prescription.
On USA, More than 250,000 women are detected with breast cancer each year and early detection is considered essential for a cure.
“We are pleased that the FDA has recognized the potential of TriNetra™ for the detection of early-stage breast cancer. We believe that TriNetra™ will offer definite benefits for breast cancer detection once it receives marketing authorization from the FDA, “said Dr. Vineet Datta, Executive Director of the Company. The Company believes that the detection of CTC is the most reliable and accurate method for the early detection of cancer, since it allows to capture and characterize the functional components of a tumor rather than fragments of dead cells. In that sense, CTCs represent a true non-invasive microbiopsy.
The test is now available at Europe and is CE marked.
About Datar Cancer Genetics
Datar Cancer Genetics is a leading cancer research corporation specializing in non-invasive techniques for better cancer diagnosis, treatment decisions, and management. The Company’s state-of-the-art cancer research center is ISO, CAP and CLIA accredited. The Company cares for cancer patients in the United Kingdom, the European Union, USA, GCC and India. The Company is conducting large clinical studies with more plans in the United States to cover multiple cancers that have the potential to be cured with early detection. The Company proposes to have multiple test centers in the United States and globally by 2024.
Dr Vineet Datta
SOURCE Datar Cancer Genetics